Skip to main content
Premium Trial:

Request an Annual Quote

Singulex, NextGen, TTP, Power3, Pressure Biosciences

Premium
Singulex Places Biomarker Platform in Novartis, Opens European Facility
 
Novartis has access to Singulex’s biomarker detection technology through Singulex’s Erenna Technology Access Program under a collaboration announced last week.
 
Singulex has placed its flagship Erenna platform in Novartis’ Basel, Switzerland, facility and will work with its researchers to develop biomarker assays to advance Novartis’ drug development program. Erenna and accompanying assays can measure very low levels of and small changes in protein biomarkers across a variety of biological samples from multiple species.
 
Financial terms of the agreement were not disclosed.
 
Singulex also announced it has opened a facility in Paris to support its European business. The facility will bring “our strong immunoassay development skills and Erenna technology closer to European partners,” Philippe Goix, president and CEO of Singulex, said in a statement.
 

 
NextGen Plans to Raise £1.5 million With Placement of Shares
 
The NextGen Group last week said that it has conditionally placed 500 million shares of its stock to an existing, unnamed shareholder at £.001 (.2 cents) a share. The placing shares will be issued at £.003 per share to raise £1.5 million ($3.1 million) before expenses.
 
The funds will be used for technology development and general working capital, the company said in a statement.
 
Additionally, for every three placing shares issued pursuant to the placing, NextGen will grant a warrant over 1 ordinary share of £.001 each with an exercise price of £.003 per share. The warrants will be exercisable for three years from the date of grant.
 

 
TTP Licenses RAP Technology, Acquires Rights to RAPid 4 Instruments
 
Inverness Medical Switzerland last week granted TTP LabTech a license to apply the Resonant Acoustic Profiling technology for drug discovery and life sciences. The technology is incorporated in the RAPid 4 instrument, TTP said.
 
Inverness acquired the RAP technology when it purchased the assets of Akubio and plans to use the technology to develop diagnostics. The assets and personnel of Akubio are now embodied in a new company, Cambridge Medical Innovations, a subsidiary of Inverness, which plans to retire the Akubio name.
 
TTP also acquired the design, manufacturing, and marketing rights to the RAPid 4 instrument, along with associated sensors and consumables from Akubio.
 
Terms of neither deal were disclosed.
 
RAP uses quartz sensor technology for the detection of molecular interactions. RAPid 4 is a flow-based analysis system which reduces the need to purify samples, TTP said in a statement, while generating kinetic, affinity, and concentration measurements from complex mixtures.
 

 
Power3 Begins Validation of Dx for Alzheimer’s, Parkinson’s
 
Power3 has begun a 300-patient clinical validation test for its blood-based NuroPro diagnostic test for Alzheimer’s and Parkinson’s disease, the company said this week.
 
The test comprises 100 patients with Alzheimer’s, 100 with Parkinson’s, and 100 controls. Marwan Sabbagh, founding director of the Cleo Roberts Center of Clinical Research at the Sun Health Research Institute in Sun City, Ariz., will serve as principle investigator.
 
The Parkinson’s component of the validation test augments another validation study currently underway at the Research Institute of Thessaly in Greece.
 
The NuPro test is based on 59 protein biomarkers discovered by Power3, which “demonstrate significant differences” in blood serum concentration of patients with Alzheimer’s and Parkinson’s in comparison to healthy patients. Power3 plans to launch the test at the conclusion of the clinical validation test, expected to happen in late-2008.
 

 
Pressure Biosciences Relocates HQ
 
Pressure Biosciences this week said it has moved its corporate offices to South Easton, Mass., “to accommodate the company’s transition from an early-stage, research and development company to a fully commercial operation.”
 
With the move, Pressure Biosciences now has 5,500 square feet. The firm had been headquartered in West Bridgewater, Mass. Its primary R&D operations will remain in Woburn, Mass., it said in a statement.